SuperworthCytosorbents profit margin CTSO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −48.9%
- Operating margin, 12 months
- −34.7%
- Net margin on a year earlier
- −21.6 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Cytosorbents kept −48.9% of its revenue as net profit, with an operating margin of −34.7% and a gross margin of 71.6%.
Five years earlier its net margin was −23.0%.
The median for 3 medical instruments and supplies stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −22.1% | −39.8% | 71.5% |
| FY2024 | −58.2% | −46.2% | 69.9% |
| FY2023 | −78.4% | −85.9% | 61.6% |
| FY2022 | −94.6% | −90.9% | 59.8% |
| FY2021 | −56.9% | −52.7% | 74.4% |
| FY2020 | −19.1% | −25.3% | 73.0% |
| FY2019 | −77.2% | −76.0% | 70.5% |
| FY2018 | −76.5% | −69.3% | 66.7% |
| FY2017 | −55.8% | −65.0% | 63.6% |
| FY2016 | n/a | n/a | 58.5% |
| FY2015 | n/a | n/a | 53.8% |
| FY2014 | n/a | n/a | 48.2% |
| FY2013 | n/a | n/a | 21.1% |
| FY2012 | n/a | n/a | 80.3% |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −48.9% | −21.6 pts | −34.7% | |
| Q1 FY26 | −31.9% | +13.7 pts | −37.4% | |
| Q4 FY25 | −22.1% | +36.1 pts | −39.8% | |
| Q3 FY25 | −27.8% | +26.3 pts | −37.2% | |
| Q2 FY25 | −27.3% | +44.6 pts | −43.6% | |
| Q1 FY25 | −45.6% | +30.4 pts | −44.4% | |
| Q4 FY24 | −58.2% | +20.2 pts | −46.2% | |
| Q3 FY24 | −54.1% | +9.2 pts | −64.0% | |
| Q2 FY24 | −72.0% | +0.7 pts | −70.8% | |
| Q1 FY24 | −76.0% | +12.0 pts | −77.9% | |
| Q4 FY23 | −78.4% | +16.2 pts | −85.9% | |
| Q3 FY23 | −63.2% | n/a | −76.0% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Cytosorbents' size, closest first, today.
| Company | Profit margin |
|---|---|
| CTSOCytosorbents | −48.9% |
| NEPHNephros | 8.4% |
| APTAlpha Pro Tech | 6.8% |
| KEQUKewaunee Scientific | 3.0% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cytosorbents
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.